ELAN Elanco Animal Health Inc

NEUTRAL Impact: 3/10 Insider Cluster (10 insiders)
Horizon days Filed May 19, 2026 Processed 17d 18h ago
Insider cluster: 2 insiders, $200K total
Latest settled — T+5d ⚠ clustered
ELAN ▲ +4.11% at T+5d
NEUTRAL call ✓ call won +4.11% · α vs SPY +3.64% · entry $23.61 → $24.58
Next anchor: T+20d in 11d
Currently $24.17 · +2.38% from $23.61 entry
Entry anchored
May 26, 2026
via day open
T+1d
+1.48%
call +1.48% · α +0.93%
$23.96
settled 17d ago
T+5d
+4.11%
call +4.11% · α +3.64%
$24.58
settled 11d ago
T+20d
call — · α —
in 11d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Elanco's CEO Jeffrey Simmons and another senior executive made open-market purchases totaling $200K on May 15. In addition, eight directors received non-cash stock grants of 4,678 shares each on May 21 — a routine director compensation event with no economic outlay. The CEO/executive buys are the sole cash transactions and represent ~0.002% of Elanco's $10.9B market cap, a trivial amount with no material signal. Historical calibration on this ticker shows prior directional calls (score=8) produced a -18% T+5 return, while score=6 calls have only a 30% T+20 win rate — suggesting strong bullish scoring on this ticker has historically underperformed. With a 91% analyst buy rating, the insider purchases appear consistent with existing bull sentiment rather than new information.

Key Financial Metrics

Direction
buying
Total Value
$200.0K
Insiders
10

Actionable Insight

CEO/executive purchases are positive but the dollar amount is trivial relative to Elanco's market cap. The buys align with the 91% bullish analyst consensus but do not signal material new information. Monitor for larger insider accumulation or the next 8-K earnings release for substantive catalysts.

Key Facts

  • CEO Jeffrey Simmons purchased 5,000 shares for ~$100K on May 15
  • Executive Modi Rajeev purchased 4,900 shares for ~$100K on May 15
  • Total open-market purchases: $200K vs $10.9B market cap = ~0.002%
  • Eight directors received identical non-cash grants of 4,678 shares each on May 21 (total $0 cash)
  • Prior ELAN reports show score=6 filings have only 30% T+20 win rate; score=8 produced -18% T+5 return

Financial Impact

Two open-market buys totaling $200K, representing ~0.002% of $10.9B market cap — de minimis. Director grants are non-cash compensation with zero economic value.

Risk Factors

  • Prior directional reads on ELAN have shown negative T+5 returns, indicating the stock may not react positively to modest insider signals
  • The $200K total purchase is 0.002% of market cap — statistically noise; overstated reaction risk
  • Director grants are routine compensation, not conviction buys

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ELAN-1779828423521
5 reports for ELAN
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+5▲ +15.03%May 19, 2026
Filters
Rows
Reports for ELAN — sortable, filterable
Type Now
May 19, 2026
24d ago
Insider Cluster
NEUTRAL ★ 3/10
$23.61 $24.58▲ +4.11%▲ +3.64%$24.17 (+2.38%)
May 19, 2026
24d ago
Insider Cluster
BULLISH ★ 4/10
$20.83 $23.69▲ +13.74%▲ +12.50%$24.17 (+16.05%)
May 19, 2026
24d ago
Insider Cluster
BULLISH ★ 5/10
$20.83 $23.96▲ +15.03%▲ +13.23%$24.17 (+16.05%)
May 6, 2026
5w ago
8-K
BULLISH ★ 8/10
$26.14 $21.43▼ −18.01%▼ −19.14%$24.17 (−7.53%)
Apr 8, 2026
9w ago
DEFA14A
NEUTRAL ★ 3/10
$23.60 $23.21▼ −1.65%▼ −5.17%$24.17 (+2.43%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (45h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access